Dr. Antonio Fojo, MD, PhD

Claim this profile

James J. Peters VA Medical Center, Bronx, NY

Studies Prostate Cancer
Studies Fanconi Anemia
3 reported clinical trials
5 drugs studied

Area of expertise

1Prostate Cancer
Antonio Fojo, MD, PhD has run 3 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
MLH1 positive
MSH2 positive
2Fanconi Anemia
Antonio Fojo, MD, PhD has run 1 trial for Fanconi Anemia. Some of their research focus areas include:
Stage IV
RAD51 positive
RAD51C positive

Affiliated Hospitals

Image of trial facility.
James J. Peters VA Medical Center, Bronx, NY
Image of trial facility.
Bronx VA Hospital

Clinical Trials Antonio Fojo, MD, PhD is currently running

Image of trial facility.

Pembrolizumab

for Prostate Cancer

The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting2 awards Phase 23 criteria
Image of trial facility.

Radium-223 + Docetaxel

for Prostate Cancer

The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria

More about Antonio Fojo, MD, PhD

Clinical Trial Related5 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Antonio Fojo, MD, PhD has experience with
  • Carboplatin
  • Olaparib
  • Pembrolizumab
  • Docetaxel
  • Radium-223

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Antonio Fojo, MD, PhD specialize in?
Is Antonio Fojo, MD, PhD currently recruiting for clinical trials?
Are there any treatments that Antonio Fojo, MD, PhD has studied deeply?
What is the best way to schedule an appointment with Antonio Fojo, MD, PhD?
What is the office address of Antonio Fojo, MD, PhD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security